BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

Compare

2,123 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

BMRN Analyst Ratings

Moderate Buy

13 Buy

5 Hold

0 Sell

Based on 18 analysts giving stock ratings to

BioMarin

Pharmaceutical

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

BMRN Stock 12 Month Forecast

Average Price Target

$94.27

▲(71.40%Upside)

Based on 18 Wall Street analysts offering 12 month price targets for BioMarin Pharmaceutical in the last 3 months. The average price target is $94.27 with a high forecast of $120.00 and a low forecast of $70.00. The average price target represents a 71.40% change from the last price of $55.00.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"56":"$56","121":"$121","72.25":"$72.3","88.5":"$88.5","104.75":"$104.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":120,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$120.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":94.27,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$94.27</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":70,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$70.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[56,72.25,88.5,104.75,121],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.05,61.89230769230769,66.73461538461538,71.57692307692308,76.41923076923077,81.26153846153846,86.10384615384615,90.94615384615385,95.78846153846155,100.63076923076923,105.47307692307692,110.31538461538462,115.15769230769232,{"y":120,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.05,59.91307692307692,62.776153846153846,65.63923076923076,68.50230769230768,71.36538461538461,74.22846153846153,77.09153846153845,79.95461538461538,82.81769230769231,85.68076923076923,88.54384615384615,91.40692307692308,{"y":94.27,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,57.05,58.04615384615384,59.04230769230769,60.03846153846153,61.034615384615385,62.03076923076923,63.026923076923076,64.02307692307693,65.01923076923077,66.01538461538462,67.01153846153846,68.00769230769231,69.00384615384615,{"y":70,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":75.07,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":82.13,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.62,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":91.21,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 47,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.1,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 63,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 23, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.6,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 46,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.04,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.73,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.36,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":71.16,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.94,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.71,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.05,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$120.00

Average Price Target$94.27

Lowest Price Target$70.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$64

Buy

16.36%

Upside

Reiterated

05/23/25

BioMarin's overall stock score reflects strong financial performance and positive earnings call sentiment as the most significant factors. Technical analysis indicates current market weakness, while valuation suggests a fair price relative to earnings. Strategic growth initiatives and global revenue diversification buffer against market uncertainties.

Gena WangBarclays

Barclays

$86

Buy

56.36%

Upside

Reiterated

06/10/25

BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays

Whitney IjemCanaccord Genuity

Canaccord Genuity

$84

Hold

52.73%

Upside

Reiterated

06/09/25

BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights

Jason GerberryBank of America Securities

Bank of America Securities

$103

Buy

87.27%

Upside

Reiterated

06/09/25

BioMarin Pharmaceutical: Navigating Competitive Challenges with Strategic Growth Potential

Vikram PurohitMorgan Stanley

Morgan Stanley

$105

Buy

90.91%

Upside

Reiterated

05/29/25

BioMarin Pharmaceutical's Promising Pipeline and Strategic Focus Justify Buy Rating

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$91

Buy

65.45%

Upside

Reiterated

05/27/25

Stifel Nicolaus Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/19/25

Truist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Kostas BiliourisBMO Capital

BMO Capital

$115

Buy

109.09%

Upside

Reiterated

05/19/25

Strategic Acquisition of INZY Boosts BioMarin's Growth Potential and Pipeline Expansion

Cory KasimovEvercore ISI

Evercore ISI

$105

Buy

90.91%

Upside

Reiterated

05/16/25

Evercore ISI on BioMarin (BMRN): INZY Acquisition Looks Like a Solid Addition to the Growing and Often Overlooked Enzyme Therapy BizEvercore ISI analyst Cory Kasimov reiterated an Outperform rating and $105.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN).

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/16/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Quanterix (NASDAQ: QTRX)

Phil NadeauTD Cowen

TD Cowen

$120

Buy

118.18%

Upside

Reiterated

05/16/25

TD Cowen reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme DealTD Cowen reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal

Sami CorwinWilliam Blair

William Blair

―

Hold

―

Reiterated

05/16/25

BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges

William PickeringBernstein

Bernstein

$94→$95

Buy

72.73%

Upside

Reiterated

05/16/25

BioMarin's Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target

Yun ZhongWedbush

Wedbush

$94

Buy

70.91%

Upside

Reiterated

05/16/25

BioMarin Pharmaceutical's Strategic Growth and Market Potential: A Buy Rating by Yun Zhong

George FarmerScotiabank

Scotiabank

$80

Hold

45.45%

Upside

Reiterated

05/02/25

Scotiabank Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$64

Buy

16.36%

Upside

Reiterated

05/23/25

Gena WangBarclays

Barclays

$86

Buy

56.36%

Upside

Reiterated

06/10/25

BioMarin Pharmaceutical (BMRN) Receives a Buy from Barclays

Whitney IjemCanaccord Genuity

Canaccord Genuity

$84

Hold

52.73%

Upside

Reiterated

06/09/25

BioMarin Pharmaceutical: Hold Rating Maintained Amid Competitive Pressures and New Data Insights

Jason GerberryBank of America Securities

Bank of America Securities

$103

Buy

87.27%

Upside

Reiterated

06/09/25

BioMarin Pharmaceutical: Navigating Competitive Challenges with Strategic Growth Potential

Vikram PurohitMorgan Stanley

Morgan Stanley

$105

Buy

90.91%

Upside

Reiterated

05/29/25

BioMarin Pharmaceutical's Promising Pipeline and Strategic Focus Justify Buy Rating

Paul MatteisStifel Nicolaus

Stifel Nicolaus

$91

Buy

65.45%

Upside

Reiterated

05/27/25

Stifel Nicolaus Sticks to Their Buy Rating for BioMarin Pharmaceutical (BMRN)

Joon LeeTruist Financial

Truist Financial

―

Buy

―

Reiterated

05/19/25

Truist Financial Reaffirms Their Buy Rating on BioMarin Pharmaceutical (BMRN)

Kostas BiliourisBMO Capital

BMO Capital

$115

Buy

109.09%

Upside

Reiterated

05/19/25

Strategic Acquisition of INZY Boosts BioMarin's Growth Potential and Pipeline Expansion

Cory KasimovEvercore ISI

Evercore ISI

$105

Buy

90.91%

Upside

Reiterated

05/16/25

Joseph SchwartzLeerink Partners

Leerink Partners

―

Buy

―

Reiterated

05/16/25

Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (NASDAQ: BMRN), ACADIA Pharmaceuticals (NASDAQ: ACAD) and Quanterix (NASDAQ: QTRX)

Phil NadeauTD Cowen

TD Cowen

$120

Buy

118.18%

Upside

Reiterated

05/16/25

TD Cowen reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme DealTD Cowen reiterates Buy Rating on BioMarin Pharmaceutical Inc. (BMRN) Following Inozyme Deal

Sami CorwinWilliam Blair

William Blair

―

Hold

―

Reiterated

05/16/25

BioMarin Pharmaceutical: Balancing Opportunities and Risks Amid Inozyme Acquisition and Market Challenges

William PickeringBernstein

Bernstein

$94→$95

Buy

72.73%

Upside

Reiterated

05/16/25

BioMarin's Strategic Acquisition of Inozyme Boosts Growth Prospects and Stock Price Target

Yun ZhongWedbush

Wedbush

$94

Buy

70.91%

Upside

Reiterated

05/16/25

BioMarin Pharmaceutical's Strategic Growth and Market Potential: A Buy Rating by Yun Zhong

George FarmerScotiabank

Scotiabank

$80

Hold

45.45%

Upside

Reiterated

05/02/25

Scotiabank Sticks to Its Hold Rating for BioMarin Pharmaceutical (BMRN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering BioMarin Pharmaceutical

1 Month

xxx

Success Rate

8/14 ratings generated profit

Average Return

-1.02%

reiterated a xxx

rating 4 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of -1.02% per trade.

3 Months

xxx

Success Rate

10/26 ratings generated profit

Average Return

-3.20%

assigned a xxx

rating 5 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 38.46% of your transactions generating a profit, with an average return of -3.20% per trade.

1 Year

Cory KasimovEvercore ISI

Success Rate

21/45 ratings generated profit

Average Return

-3.75%

reiterated a buy rating last month

Copying Cory Kasimov's trades and holding each position for 1 Year would result in 46.67% of your transactions generating a profit, with an average return of -3.75% per trade.

2 Years

xxx

Success Rate

9/24 ratings generated profit

Average Return

-10.05%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 37.50% of your transactions generating a profit, with an average return of -10.05% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BMRN Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, BMRN has received 25 Buy Ratings, 8 Hold Ratings, and 0 Sell Ratings. BMRN average Analyst price target in the past 3 months is 94.27.

Each month's total comprises the sum of three months' worth of ratings.

BMRN Financial Forecast

BMRN Earnings Forecast

Next quarter’s earnings estimate for BMRN is $0.84 with a range of $0.59 to $0.97. The previous quarter’s EPS was $0.95. BMRN beat its EPS estimate 100.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.09% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.

BMRN Sales Forecast

Next quarter’s sales forecast for BMRN is $761.34M with a range of $735.73M to $778.00M. The previous quarter’s sales results were $732.60M. BMRN beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.49% of the time in the same period. In the last calendar year BMRN has Outperformed its overall industry.

BMRN Stock Forecast FAQ

What is BMRN’s average 12-month price target, according to analysts?

Based on analyst ratings, BioMarin Pharmaceutical’s 12-month average price target is 94.27.

What is BMRN’s upside potential, based on the analysts’ average price target?

BioMarin Pharmaceutical has 71.40% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is BMRN a Buy, Sell or Hold?

BioMarin Pharmaceutical has a consensus rating of Moderate Buy which is based on 13 buy ratings, 5 hold ratings and 0 sell ratings.

What is BioMarin Pharmaceutical’s price target?

The average price target for BioMarin Pharmaceutical is 94.27. This is based on 18 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $120.00 ,the lowest forecast is $70.00. The average price target represents 71.40% Increase from the current price of $55.

What do analysts say about BioMarin Pharmaceutical?

BioMarin Pharmaceutical’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 18 Wall Streets Analysts.

How can I buy shares of BMRN?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

BioMarin Pharmaceutical (BMRN) Stock Forecast & Price Target

BMRN Analyst Ratings

BMRN Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering BioMarin Pharmaceutical

BMRN Analyst Recommendation Trends

BMRN Financial Forecast

BMRN Earnings Forecast

BMRN Sales Forecast

BMRN Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts